Piper Sandler cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from an overweight rating to a neutral rating in a research report report published on Wednesday morning, Marketbeat.com reports. The firm currently has $36.00 price objective on the specialty pharmaceutical company’s stock, down from their prior price objective of $41.00.
Separately, StockNews.com raised shares of Supernus Pharmaceuticals from a buy rating to a strong-buy rating in a report on Wednesday, August 7th.
Get Our Latest Stock Analysis on Supernus Pharmaceuticals
Supernus Pharmaceuticals Trading Down 7.2 %
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The firm had revenue of $168.30 million during the quarter, compared to analysts’ expectations of $148.83 million. During the same period in the prior year, the company posted ($0.02) EPS. The company’s revenue for the quarter was up 24.1% compared to the same quarter last year. Equities research analysts predict that Supernus Pharmaceuticals will post 1.56 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Fidelis Capital Partners LLC purchased a new position in Supernus Pharmaceuticals during the first quarter worth about $33,000. Quadrant Capital Group LLC boosted its stake in Supernus Pharmaceuticals by 1,117.6% during the fourth quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 1,330 shares during the period. EntryPoint Capital LLC purchased a new position in Supernus Pharmaceuticals during the first quarter worth about $43,000. Meeder Asset Management Inc. purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $47,000. Finally, Innealta Capital LLC purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $51,000.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Recommended Stories
- Five stocks we like better than Supernus Pharmaceuticals
- Investing in Commodities: What Are They? How to Invest in Them
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Canada Bond Market Holiday: How to Invest and Trade
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.